{"id":"W4397007360","doi":"10.1016/j.esmoop.2024.103115","title":"127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Atezolizumab; Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001228156,0.0004168873,0.0008944388,0.0002562385,0.0001708914,0.0002328508,0.001158225,0.0001846439,0.002974812],"category_scores_gemma":[0.0001485567,0.0002810836,0.0003154597,0.001186275,0.0003541566,0.0003401297,0.0004234584,0.001142546,0.00007483771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001675385,"about_ca_system_score_gemma":0.003426744,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.065205,"about_ca_topic_score_gemma":0.003615269,"domain_scores_codex":[0.9957876,0.0003944414,0.0009706236,0.0009109854,0.001159863,0.0007765058],"domain_scores_gemma":[0.998099,0.0002554736,0.0001834287,0.000956159,0.0002199973,0.0002859454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4363787,0.004013265,0.001839225,0.0004856397,0.001012458,0.001579375,0.01247128,0.00004686016,0.004554007,0.0005543319,0.1129562,0.4241087],"study_design_scores_gemma":[0.6153115,0.0100652,0.185781,0.01080922,0.0004089309,0.001079034,0.001464367,0.00307575,0.03382972,0.0005321154,0.1362422,0.001400878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9559836,0.0006790477,0.00001699845,0.0238294,0.00101615,0.005120771,0.001013044,0.00007188387,0.01226907],"genre_scores_gemma":[0.9876044,0.0003791358,0.000064726,0.0004186587,0.0006885946,0.0006075981,0.00005554497,0.0001134265,0.01006796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4227078,"threshold_uncertainty_score":0.9999641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0517048107338275,"score_gpt":0.4141104975485573,"score_spread":0.3624056868147298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}